HeartSciences Inc Dossier
Qualitative Analysis
Business overview
HeartSciences Inc. (formerly known as Heart Test Laboratories, Inc.) is a clinical-stage medical technology company specializing in artificial intelligence-enhanced electrocardiography (AI-ECG) solutions. Headquartered in Southlake, Texas, the company is focused on bridging the gap between traditional electrocardiograms (ECGs/EKGs) and modern AI to enable the early detection of heart disease, particularly left ventricular diastolic dysfunction (LVDD). Its core product offerings include the MyoVista wavECG device—a resting 12-lead ECG utilizing continuous wavelet transform (CWT) signal processing to analyze cardiac energy distribution—and MyoVista Insights, a cloud-native, hardware-agnostic software platform designed to host proprietary and third-party AI-ECG algorithms.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a single-device hardware focus to a cloud-native, hardware-agnostic AI-ECG platform strategy. The platform hosts both proprietary and third-party AI-ECG algorithms, creating a marketplace for clinical applications that can accept ECGs from millions of existing devices worldwide.
Expected impact: Establishes a recurring, SaaS-based revenue model by charging on a per-test or subscription basis for hosted algorithms, leveraging Medicare reimbursement under APC 5734.
Partnering with Cibolo Health to enable its member hospitals to modernize legacy ECG workflows using the MyoVista Insights platform.
Expected impact: Provides a structured commercial pathway to deploy MyoVista Insights across Cibolo's network of over 120 independent rural hospitals.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants HeartSciences rights to a massive library of patented and unpatented AI-based ECG/EKG algorithms and technologies for screening and diagnosing cardiovascular disease, while making Mount Sinai a shareholder in the company.
Terms: Mount Sinai received equity shares in HeartSciences in exchange for the algorithm licenses.
Integrates Bunkerhill's FDA-cleared ECG-EF algorithm for detecting reduced left ventricular ejection fraction (LVEF ≤40%) as the first cleared third-party algorithm on the MyoVista Insights marketplace.
Terms: SaaS-based revenue sharing model on assessments performed using the algorithm.